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Comparisons of survival rates of given diseases with different treatments or in different places often gave misleading results until the
introduction of controlled trials. Recent reports of relatively low survival rates following the treatment of cancer in the UK compared
to the rates in other countries, not based on controlled trials, may consequently be misleading. Their validity has, therefore, been
tested by comparing the levels and trends in mortality – the ultimate criterion by which the success or failure of any system of care
can be judged. For this purpose, rates and trends in rates over 20–50 years have been compared in five European countries of similar
economic status (France, Italy, the Netherlands, Sweden, and the UK). The UK rates are not generally worse than those in the other
countries and are sometimes better. Exceptions were cancer of the lung, large bowel, and breast, the first of which is explained by
differences in the prevalence of smoking.
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Comparisons of the incidence and mortality rates of a variety of
diseases in different populations have provided important clues to
their causation. The differences have often been large – sometimes
several hundred fold for the incidence of different types of cancer –
and there has been little difficulty in establishing that they were
genuine. Comparison of national differences in survival are similarly
useful to assess the adequacy and competence of medical care under
different systems of organisation; but the differences between the
results in different developed countries are unlikely to have been
large and they are much more difficult to establish. It is nevertheless
worrying when reports suggested that survival rates have been lower
in the UK than in some other European countries (Sant et al, 2003).
However, were the survival rates truly comparable?
We have long known how unreliable reports of differences in
survival have been when different treatments have been used by
different people or in different institutions and that reliable
comparisons came to be made only when the principle of controlled
trials was accepted. Unfortunately, that method is not available for
testing the efficacy of treatment in whole countries, and we have to
make do as best we can with what limited evidence is available.
Fortunately, the treatment of many types of cancer has become
more effective in the last 20 years and we can at least see whether
or not the trends in mortality have been equally favourable in the
countries whose medical care we want to compare. For mortality
rates in developed countries are reasonably reliable, although they
can be occasionally distorted by artefacts and we need always to
bear that possibility in mind when odd divergences unexpectedly
occur. They are, of course, also affected by differences in
incidence. These, however, are, for the most part, not large within
Europe, ranging up to five-fold, and are unlikely to have had much
effect on differences in the trends in mortality, apart from those for
cancers closely related to smoking and the consumption of alcohol,
most notably for cancer of the lung.
METHODS
In this paper, I compare only the trends in mortality in a few
selected countries. To compare with the UK, I have chosen four
other countries in the European Union, without any prior
knowledge of what the results would be, requiring only that the
countries would be of roughly similar economic status: namely,
France, Italy, The Netherlands, and Sweden. I would have chosen
Germany, but the changes that occurred with the reunification of
the East and the West made this impossible, as I wished to trace
the trends over the whole of the last 50 years. Trends must be
studied in both sexes, but it is not obvious what age groups are the
most appropriate to compare. For studying the causes of disease
these should certainly be relatively young, partly because incidence
rates are less reliable in old age but primarily because rates in the
young are more closely related to current conditions than the rates
in the old. I doubt, however, if such rates would be appropriate for
assessing the effects of treatment, as most cancers occur in the
relatively old and one of the most important tests of the efficiency
of a system of medical care is the provision it makes for the old. I
have, therefore, compared the trends in mortality for all ages
combined, standardising for age with the conventional European
age distribution used by the World Health Organisation.
COMPARISION OF TRENDS IN MORTALITY
Two uncommon types of cancer
I examine first two relatively uncommon types of cancer for which
new treatments have had a major effect on survival: namely cancer
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Figure 1 Five EU countries, 1979–2001, Males: testis cancer mortality at
all ages. *Annual rates per 100000 men, standardised to conventional
European age distribution. Source: WHO mortality and UN population
estimates.
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Figure 2 Five EU countries, 1979–2002, Males: Hodgkin’s disease
mortality at all ages. *Annual rates per 100000 men, standardised to
conventional European age distribution. Source: WHO mortality and UN
population estimates.
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Figure 3 Five EU countries, 1979–2002, Females: Hodgkin’s disease
mortality at all ages. *Annual rates per 100000 women, standardised to
conventional European age distribution. Source: WHO mortality and UN
population estimates.
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Figure 4 Five EU countries, 1950–2002, Males: stomach cancer
mortality at all ages. *Annual rates per 100000 men, standardised to
conventional European age distribution. Source: WHO mortality and UN
population estimates.
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examined only the rates since the mid-1970s when the new
treatments came into common use.
The data for testis cancer are shown in Figure 1. All five
countries seem to have used the new treatments to much the same
extent, with the UK trends in mortality near the middle. Figures 2
and 3 show the data for Hodgkin’s disease separately for males and
females. The reduction in mortality has again been much the same
in all five countries since about 1985 with the British data near the
middle. Before then the Italian data were exceptionally high due,
according to La Vecchia (personal communication), to delay in
adopting efficacious modern therapies in some parts of the
country and partly to some national quirk of classification.
Five common cancers
If now we consider the five most common cancers, there are
two whose trends are dominated by changes in incidence:
cancers of the stomach and lung. In both cases we can trace the
trends since 1950.
Cancer of stomach With cancer of the stomach, the trends are the
same in both sexes. Figure 4 shows the trends in men, with an
astonishing reduction of about 80% over the period and with the
UK data firmly in the middle. Whether improvements in treatment
have played any material part may be open to doubt, but if they
have there is no reason to suppose that they have been less in the
UK than elsewhere – except perhaps than in Japan, whose data are
not shown, where the incidence has been much higher than in
Europe and intensive efforts have been made to treat the disease
early in its history. Why there has been such a large and continued
reduction in incidence is still uncertain. It seems to have been
associated with the progressive increase in refrigeration and the
abandonment of other forms of food preservation, the somewhat
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Figure 5 Five EU countries, 1950–2002, Females: stomach cancer
mortality at all ages. *Annual rates per 100000 women, standardised to
conventional European age distribution. Source: WHO mortality and UN
population estimates.
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Figure 6 Five EU countries, 1950–2002, Males: lung cancer mortality at
all ages. *Annual rates per 100000 men, standardised to conventional
European age distribution. Source: WHO mortality and UN population
estimates.
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Figure 7 Five EU countries, 1950–2002, Females: lung cancer mortality
at all ages. *Annual rates per 100000 women, standardised to conventional
European age distribution. Source: WHO mortality and UN population
estimates.
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Figure 8 Trends in lung cancer at ages 40–44 and past cigarette smoking in men and women in France 1950–2000. (A) Average number of cigarettes
per day between age 15 and 42.5, population aged 40–44. (B) Lung cancer death rate, population aged 40–44.
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Figure 9 Five EU countries, 1950–2002, Females: breast cancer
mortality at all ages. *Annual rates per 100000 women, standardised to
conventional European age distribution. Source: WHO mortality and UN
population estimates.
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Figure 10 Five EU countries, 1950–2002, Males: prostate cancer
mortality at all ages. *Annual rates per 100000 men, standardised to
conventional European age distribution. Source: WHO mortality and UN
population estimates.
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preserved food in the mountainous areas. A reduction in the
prevalence of gastric infection with Helicobacter pylori will also
have contributed.
Figure 5 shows that the trends have been almost identical in
women.
Cancer of the lung Unlike that for cancer of the stomach, the
principal cause of cancer of the lung has varied in prevalence at
different times in each country and in both sexes. There may have
been some improvement in the outlook for some types of the
disease in the hands of the ultraspecialist, but any such
improvement can be detected only by controlled trials and is
certainly too small to have made any detectable impact on the
national mortality rate.
Figure 6 shows the trends over the last 50 years in men. Cigarette
smoking became common first in the UK and the lung cancer
mortality mounted steadily, at first in young men and then in the
elderly until the time came that they had been smoking cigarettes
from early in life. Separate examination by age and socioeconomic
status shows that some reduction began in the young soon after the
war, as a large price increase caused the young to reduce smoking
and the very high tar content of the prewar cigarettes was, for some
non-medical reason, reduced, while the most educated, who were
most responsive to the spread of education, began to give up. It
was not, however, until the early 1970s when the media were
themselves convinced of the importance of the relationship and
gave a clear message in the press and on the television that
increasingly large numbers of smokers stopped smoking and a
decline began to be seen progressively at all ages. The adoption
and decline of cigarette smoking followed later in most other
countries, but the habit never became really popular among
Swedish men.
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Figure 11 Five EU countries, 1950–2002, Males: colorectal cancer
mortality at all ages. *Annual rates per 100000 men, standardised to
conventional European age distribution. Source: WHO mortality and UN
population estimates.
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Figure 12 Five EU countries, 1950–2002, Females: colorectal cancer
mortality at all ages. *Annual rates per 100000 women, standardised to
conventional European age distribution. Source: WHO mortality and UN
population estimates.
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Figure 13 Five EU countries, 1950–2002, Males: all cancer (excl. lung)
mortality at all ages. *Annual rates per 100000 men, standardised to
conventional European age distribution. Source: WHO mortality and UN
population estimates.
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yFigure 7, which is on a different scale, reflects the later
development of smoking in women, in whom the risk in the four
countries other than the UK is still rising.
The close association between risk of lung cancer and the
amount smoked is beautifully illustrated by the demonstration of
the relationship between the risk in young men in France and their
estimated lifetime consumption of cigarettes shown in Figure 8
(Hill and Laplanche, personal communication).
Cancer of the breast Two other types of cancer are more
pertinent for the purpose of this review as the recent trends in
their mortality have been affected principally by the efficiency of
treatment: namely, cancers of the breast and prostate. The trends
for the former are shown in Figure 9. The hump in UK mortality
between 1984 and 1992 is an artefact due to a change in the rule
allocating the underlying cause of death when cancer was
mentioned on the death certificate as an associated cause. The
Registrar-General for England and Wales, who had changed
the rule, hoped that other countries would follow suit; but
they did not and he quickly returned to the old rules laid
down by the World Health Organisation. Whether the relatively
high mortality in the Netherlands and the UK between 1950
and 1990 reflected a higher incidence or less effective treatment
is a moot point. There is some evidence that the incidence has
been unusually high in the Netherlands, but not in the UK
(International Agency for Research on Cancer, 1992). Whatever
the explanation, however, the sharp drop in mortality since
1990 has brought the UK rate close to those of Italy and France.
The fall is principally due to the increased use of chemo-
therapy and particularly the intensive and prolonged use of
tamoxifen, which was uncommon in the UK until the combined
results of the Early Breast Cancer Trialists Collaborative
Group (1988) were publicised. Some contribution is also likely
to have come from increased specialist care and the more
extensive use of mammography, but the latter would not have
affected all the age groups in which a reduction in mortality
has been seen.
Cancer of the prostate Figure 10 shows the trends for prostate
cancer. They are truly remarkable. We see again the small artificial
hump in the British data between 1984 and 1992, but are also faced
with the extraordinary hump in the Swedish data in the 1970s.
According to Professor Ekbom (personal communication), the
changes that took place in and after the 1950s can be largely
explained by effects on death certification of major changes in
the method of medical re-imbursement, the frequency of biopsy,
and methods of operation, affected possibly in part by PSA
measurements.
Mortality rates in France, the Netherlands, and the UK all
showed a substantial rise in the 1980s, before there began to
be a fall due almost certainly to chemotherapy, which is shown
most clearly, as with breast cancer, by the data for relatively
young age groups in which treatment has been more aggressive.
However, whatever the explanation for these complex trends
there is nothing to suggest that British survival rates have been
unusually poor.
Colorectal cancer The last of the major causes for which I have
sought specific figures is cancer of the large bowel. The trends are
shown in Figures 11 and 12. I have no explanation for the low rates
in Italy before 1970, but the sharp drop in mortality in the late
1970s can be explained as an artefact resulting from the belated
recognition that cancers of the small bowel and of the intestine
unspecified should not have been included with the specific data
for cancers of the large bowel. For the purpose of the present
review it is notable that the rates in all five countries are now much
the same with the UK rates firmly in the middle.
All cancers other than lung cancer
For all cancers combined the trends are materially affected by
those for lung cancer, which have little bearing on the efficiency of
diagnosis and treatment. I have examined, therefore, only the
trends for all cancers other than lung cancer, which are shown for
men in Figure 13 and for women in Figure 14.
Those for men show the artificial hump in Sweden in the 1970s
and consistently high figures for France, reducing substantially
since 1985, which may be due to the recent reduction in the
previously high consumption of alcohol and its consequent effect
on the mortality from cancers of the mouth, pharynx, larynx,
oesophagus and liver. The UK figures have been the lowest but
one since the 1960s and show no tendency to depart from
that position. The trends for women, though consistently down-
ward for all five countries since the mid-1980s, are less satisfactory
for the UK. The current rates are slightly higher than those
for Italy, France and Sweden and equal highest with those for
the Netherlands, due possibly to the prevalence of smoking by
women, as smoking contributes to many types of cancer other than
cancer of the lung.
CONCLUSION
The British rates for the mortality from cancer, which is the
ultimate criterion by which the success or failure of any system of
care and therapy for patients with cancer has to be judged, are not
generally worse than those in other economically comparable
European countries, and, indeed, are sometimes better. This was
not so for the trends in breast and colorectal cancer before 1990
and the recent decline in the mortality from both these diseases
may reflect improvements in treatment and consequently in
survival.
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Figure 14 Five EU countries, 1950–2002, Females: all cancer (excl. lung)
mortality at all ages. *Annual rates per 100000 women, standardised to
conventional European age distribution. Source: WHO mortality and UN
population estimates.
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